Abstract
RNA interference (RNAi) is a collection of small RNA-directed mechanisms that result in sequence-specific inhibition of gene expression. RNAi delivery has demonstrated promising efficacy in the treatment of genetic disorders in cancer. Although viral vectors are currently the most efficient systems for gene therapy, potent immunogenicity, mutagenesis, and the biohazards of viral vectors remain their major risks. Various non-viral delivery vectors have been developed to provide a safer approach for gene delivery, including polymers, peptides, liposomes, and nanoparticles. However, some concerns and challenges of these non-viral gene delivery approaches remain to be overcome. In this review, we summarize the recent progress in the development of non-viral systems delivering RNAi and the currently available preclinical and clinical data, and discuss the challenges and future directions in cancer therapy.
Keywords: Cancer gene therapy, liposomes, microRNA, non-viral delivery, nuclear localization signal, polymers, RNA interference, siRNA.
Current Gene Therapy
Title:Non-Viral Delivery of RNA Interference Targeting Cancer Cells in Cancer Gene Therapy
Volume: 12 Issue: 4
Author(s): Pin-I Huang, Wen-Liang Lo, Jong-Yuh Cherng, Yueh Chien, Guang-Yuh Chiou and Shih-Hwa Chiou
Affiliation:
Keywords: Cancer gene therapy, liposomes, microRNA, non-viral delivery, nuclear localization signal, polymers, RNA interference, siRNA.
Abstract: RNA interference (RNAi) is a collection of small RNA-directed mechanisms that result in sequence-specific inhibition of gene expression. RNAi delivery has demonstrated promising efficacy in the treatment of genetic disorders in cancer. Although viral vectors are currently the most efficient systems for gene therapy, potent immunogenicity, mutagenesis, and the biohazards of viral vectors remain their major risks. Various non-viral delivery vectors have been developed to provide a safer approach for gene delivery, including polymers, peptides, liposomes, and nanoparticles. However, some concerns and challenges of these non-viral gene delivery approaches remain to be overcome. In this review, we summarize the recent progress in the development of non-viral systems delivering RNAi and the currently available preclinical and clinical data, and discuss the challenges and future directions in cancer therapy.
Export Options
About this article
Cite this article as:
Huang Pin-I, Lo Wen-Liang, Cherng Jong-Yuh, Chien Yueh, Chiou Guang-Yuh and Chiou Shih-Hwa, Non-Viral Delivery of RNA Interference Targeting Cancer Cells in Cancer Gene Therapy, Current Gene Therapy 2012; 12 (4) . https://dx.doi.org/10.2174/156652312802083576
DOI https://dx.doi.org/10.2174/156652312802083576 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MicroRNA Targeting as a Therapeutic Strategy Against Glioma
Current Molecular Medicine Ornithine Decarboxylase Inhibition: A Strategy to Combat Various Diseases
Mini-Reviews in Medicinal Chemistry NEDD4: A Promising Target for Cancer Therapy
Current Cancer Drug Targets The PI3K/Akt Pathway as a Target in the Treatment of Hematologic Malignancies
Anti-Cancer Agents in Medicinal Chemistry Current Inhibitors of Checkpoint Kinase 2
Current Medicinal Chemistry Withdrawal Notice: Circulatory Cells as Tumortropic Carrier for Targetability Improvement
Current Drug Delivery Modulation of the Cannabinoid System: A New Perspective for the Treatment of the Alzheimer’s Disease
Current Neuropharmacology Electroporation Advances in Large Animals
Current Gene Therapy Synergistic Interaction of Telomerase-Specific Oncolytic Virotherapy and Chemotherapeutic Agents for Human Cancer
Current Pharmaceutical Biotechnology The PI3K/Akt Pathway: Recent Progress in the Development of ATP-Competitive and Allosteric Akt Kinase Inhibitors
Current Cancer Drug Targets Synthesis and Evaluation of <sup>198</sup>Au/PAMAM-MPEG-FA against Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells
Current Medicinal Chemistry Focus on the Role of Glutamate in the Pathology of the Peripheral Nervous System
CNS & Neurological Disorders - Drug Targets Melatonin Receptor as a Drug Target for Neuroprotection
Current Molecular Pharmacology Progress in Developing Amphiphilic Cyclodextrin-Based Nanodevices for Drug Delivery
Current Topics in Medicinal Chemistry Pharmacogenomics of Non-Small Cell Lung Cancer
Current Pharmacogenomics An Investigative Approach to Treatment Modalities for Squamous Cell Carcinoma of Skin
Current Drug Delivery Potential Role of <i>In Vitro-In Vivo</i> Correlations (IVIVC) for the Development of Plant-Derived Anticancer Drugs
Current Drug Targets Neuroprotection & Mechanism of Ethanol in Stroke and Traumatic Brain Injury Therapy: New Prospects for an Ancient Drug
Current Drug Targets Lipoic Acid: A Novel Therapeutic Approach for Multiple Sclerosis and Other Chronic Inflammatory Diseases of the CNS
Endocrine, Metabolic & Immune Disorders - Drug Targets